Boston Scientific Corp (BSX.N)
9.23USD
1:30am IST
$-0.02 (-0.22%)
$9.25
$9.26
$9.38
$9.18
3,800,537
3,039,522
$9.38
$4.79
BSX.N
About
Overall
| Beta: | 1.21 |
| Market Cap (Mil.): | $14,340.75 |
| Shares Outstanding (Mil.): | 1,550.35 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
UPDATE 2-Boston Scientific says on path to growth
April 25 - Medical device maker Boston Scientific Corp reported better-than-expected first-quarter results on Thursday, which the company said will put it on the path to return to growth.
Boston Scientific posts first-quarter loss
April 25 - Medical device maker Boston Scientific Corp on Thursday posted a first-quarter loss due to $578 million in restructuring, litigation and other charges.
Boston Scientific atrial fibrillation device proves safe -study
SAN FRANCISCO/CHICAGO, March 9 - A tiny upside down umbrella-shaped device implanted on the heart to prevent stroke in patients with a dangerous irregular heart rhythm known as atrial fibrillation appeared to be safe in a highly anticipated clinical trial, providing an alternative to clot-preventing blood thinners.
Boston Scientific atrial fibrillation device proves safe -study
* Rate of death, stroke, complications within 7 days 4.6 pct vs 8.7
Boston Scientific sees market share growth in heart devices
- Medical device maker Boston Scientific Corp said it expects to grow faster than the overall market for implantable heart devices, which has been struggling in recent years amid weak worldwide demand.
Boston Scientific sees market share growth in heart devices
Feb 12 - Medical device maker Boston Scientific Corp said it expects to grow faster than the overall market for implantable heart devices, which has been struggling in recent years amid weak worldwide demand.
UPDATE 3-Boston Scientific outlook cheers investors; stock rises
* Fourth-quarter net income falls to 4 cents a share from 7 cents
Boston Scientific posts weaker quarterly results
Jan 29 - Boston Scientific Corp on Tuesday posted weaker quarterly earnings as sales slipped and expenses rose.
Doctor urges limited use of Boston Scientific's new device
CHICAGO - Boston Scientific Corp's new leadless implantable heart defibrillator, hailed by some as a breakthrough, should be used on a limited basis until more data are collected, a prominent cardiologist wrote in an editorial of a top medical journal.
UPDATE 2-Doctor urges limited use of Boston Scientific's new device
CHICAGO, Jan 2 - Boston Scientific Corp's new leadless implantable heart defibrillator, hailed by some as a breakthrough, should be used on a limited basis until more data are collected, a prominent cardiologist wrote in an editorial of a top medical journal.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $88.59 | +0.58 |
| Medtronic, Inc. (MDT.N) | $52.35 | +2.46 |
| Abbott Laboratories (ABT.N) | $37.72 | -0.09 |
| St. Jude Medical, Inc. (STJ.N) | $46.78 | +0.06 |
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
